On Thursday, Delek US Holdings, Inc. (NYSE:DK)’s shares inclined 1.09% to $29.55.
Delek US Holdings, Inc. (DK) declared financial results for its second quarter ended June 30, 2015. Delek US stated a second quarter net income of $48.3 million, or $0.79 per diluted share, as compared to net income of $54.9 million, or $0.92 per diluted share, for the quarter ended June 30, 2014. Operating income in the second quarter 2014 comprised of a one-time non-cash expense of about $22.6 million before tax related to the financial settlement under the restated supply and offtake agreement with J Aron.
Second quarter 2015 results comprised of a $15.3 million net hedging loss, of which $13.4 million was unrealized. There was about $22.8 million of costs that reduced performance in the period, which comprises the unrealized hedging loss, expenses related to the Alon USA transaction, higher depreciation due to asset disposals and unanticipated pipeline related expenses.
Delek US Holdings, Inc. operates as an integrated downstream energy company that operates in petroleum refining, wholesale distribution, and convenience store retailing businesses. The company operates in three segments: Refining, Logistics, and Retail. The Refining segment owns and operates two refineries in Tyler, Texas, and El Dorado, Arkansas; and produces various petroleum-based products used in transportation and industrial markets.
Galena Biopharma In c(NASDAQ:GALE)’s shares showed no change to $1.62.
Galena Biopharma , Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, stated its financial results for the quarter ended June 30, 2015 and offered a business update.
FINANCIAL HIGHLIGHTS AND GUIDANCE
Operating loss for the second quarter of 2015 was $11.3 million, counting $0.6 million in stock based compensation, contrast to an operating loss of $15.8 million, counting $1.5 million in stock-based compensation for the same period last year. Operating loss for the first half of 2015 was $22.4 million, counting $1.3 million in stock based compensation, contrast to an operating loss of $27.6 million, counting $3.2 million in stock-based compensation for the same period in 2014. The decrease in net operating loss year-over-year is primarily the result of the completion of enrollment in our Phase 3 PRESENT trial for NeuVax, in addition to the decrease in stock based compensation and professional fees associated with ongoing legal proceedings.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
At the end of Thursday’s trade, Stillwater Mining Company (NYSE:SWC)‘s shares surged 0.32% to $9.29.
Stillwater Mining Company (SWC) stated financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Highlights:
- Processed 151,600 ounces of recycled palladium, platinum and rhodium, an enhance of 12.9% over 134,300 ounces recycled during the second quarter of 2014.
- Merged net loss attributable to common stockholders of $27.5 million or $0.23 per share, counting a $46.8 million (before-tax) impairment charge taken on the Marathon mineral properties.
- Mined palladium and platinum production of 127,000 ounces, a slight enhance from 126,400 ounces mined during the second quarter of 2014.
- All-in Sustaining Costs (AISC)* of $785 per mined ounce of palladium and platinum, contrast to $792 per mined ounce for the second quarter of 2014.
- Cash and cash equivalents plus highly liquid investments of $531.2 million at quarter end, after $11.0 million enhance in recycle working capital during the second quarter.
- Labor contract with employees expired during the quarter; represented employees at the Stillwater Mine and Columbus processing facilities continue to work under the terms of the previous agreement.
Stillwater Mining Company engages in the development, extraction, processing, smelting, and refining of platinum group metals (PGMs). It operates through Mine Production, PGM Recycling, Canadian Properties, and South American Properties segments. The company primarily explores for palladium, platinum, and associated metals, in addition to for nickel, copper, gold, silver, and rhodium ores.
Organovo Holdings Inc (NYSEMKT:ONVO), ended its Thursday’s trading session with -5.30% loss, and closed at $2.50.
Organovo Holdings, Inc. (ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, recently stated its financial results for the first quarter of fiscal 2016 ended June 30, 2015.
Recent Corporate Highlights Comprised of:
- Celebrated the successful launch of its exVive3DTMHuman Liver Tissue, with an declarement of the launch results showing about $2 million in total contract bookings as of June 9, 2015.
- Presented data on the Company’s in vitrothree-dimensional kidney tissue at the 2015 Experimental Biology conference in Boston, Massachusetts, demonstrating fully human kidney proximal tubular tissues were generated that were three-dimensional, and compriseed of multiple tissue-relevant cell types arranged to recapitulate the renal tubular/interstitial interface. This breakthrough result demonstrated a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo.
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
